Patrick Baeuerle
Founder at iOmx Therapeutics AG
Net worth: 8 M $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ansbert Gadicke | M | 66 |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 32 years |
| Luke Evnin | M | 60 |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 27 years |
| Anthony Adam Rosenberg | M | 71 |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts.
iOmx Therapeutics AG
 iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | 9 years |
| Stephen Webster | M | 63 | 4 years | |
| Julia Eastland | F | 59 | 6 years | |
| Kristen Laguerre | F | - |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 7 years |
| Thomas Ebeling | M | 65 |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 7 years |
| Nadim Ahmed | M | 56 | 3 years | |
| David Ryan | M | 57 |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 2 years |
| Briggs Morrison | M | 65 |
Crossbow Therapeutics, Inc.
 Crossbow Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Crossbow Therapeutics, Inc. is a biotechnology company that aims to improve the lives of people with cancer by developing next-generation immunotherapies. The company is based in Cambridge, MA, and the CEO of the company is Briggs W. Morrison. The company's T-bolt™ therapies are designed to target previously unreachable cancer cell targets with high precision. Crossbow's approach is efficient and selective, allowing them to target the entire universe of cancer proteins, which expands the potential of antibody therapy to address many types of cancer.
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 9 years |
| Jacquelyn Sumer | F | 46 | 2 years | |
| Philipp Beckhove | M | - |
iOmx Therapeutics AG
iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | 8 years |
| Apollon Papadimitriou | M | - |
iOmx Therapeutics AG
iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | 7 years |
| Bengt Westermark | M | 79 |
European Molecular Biology Organization
| - |
| Henrijette Richter | M | 53 |
iOmx Therapeutics AG
iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | - |
| Detlev Biniszkiewicz | M | 56 |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 3 years |
| Frank Lanza | M | 62 | 5 years | |
| Rami Rahal | M | - |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 2 years |
| Jennifer Michaelson | M | 57 | 6 years | |
| Peter Olagunju | M | - | 3 years | |
| Margaret Siegel | F | - | 6 years | |
| Todd Foley | M | 52 |
Crossbow Therapeutics, Inc.
Crossbow Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Crossbow Therapeutics, Inc. is a biotechnology company that aims to improve the lives of people with cancer by developing next-generation immunotherapies. The company is based in Cambridge, MA, and the CEO of the company is Briggs W. Morrison. The company's T-bolt™ therapies are designed to target previously unreachable cancer cell targets with high precision. Crossbow's approach is efficient and selective, allowing them to target the entire universe of cancer proteins, which expands the potential of antibody therapy to address many types of cancer.
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 25 years |
| Anne-Marie Martin | M | 52 | 2 years | |
| Alim Ladha | M | - |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | - |
| Erich Maximilian Platzer | M | 74 |
TeGenero AG
 TeGenero AG Pharmaceuticals: MajorHealth Technology TeGenero AG discovers and develops novel therapeutics. It is a biopharmaceutical company providing services in the identification and development of effective and applicable therapeutics for the treatment of severe immunological disorders. It's first development candidate TGN1412, a SuperMAB with specificity for the T cell surface receptor CD28 is in non-clinical development. Clinical applications of SuperMAB and its derived compounds are expected to solve unmet medical needs in the fields of cancer-related immunodeficiencies such as B-cell chronic lymphocytic leukaemia and autoimmune/inflammatory diseases like rheumatoid arthritis. The company was founded in 2000 and is headquartered in Wurzburg, Germany.
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | 9 years |
| Devin Quinlan | M | - |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 6 years |
| Brian Goodman | M | - |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 5 years |
| David Kolesky | M | - |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 1 years |
| Brendan Furey | M | - |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 2 years |
| Gregg McConnell | M | - | 4 years | |
| Florencia Segal | M | - |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 2 years |
| John Baclawski | M | - |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 1 years |
| Kevin Zikaras | M | - | 6 years | |
| Viera Muzithras | M | - | 4 years | |
| Richard Roomberg | M | - | 5 years | |
| Andrew Scharenberg | M | - |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 5 years |
| Rose Weldon | F | - | 2 years | |
| Hong Wu | M | 66 |
European Molecular Biology Organization
| 8 years |
| Holger Wesche | M | 56 | 6 years | |
| Fulvio Mavilio | M | - |
European Molecular Biology Organization
| - |
| Corinne Savill | M | 64 | 7 years | |
| Ashok Venkitaraman | M | - |
European Molecular Biology Organization
| - |
| Edward Hurwitz | M | 60 |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 7 years |
| David Glover | M | - |
European Molecular Biology Organization
| - |
| Hans Lennart Rudolf Wigzell | M | 86 |
European Molecular Biology Organization
| - |
| Daniel L. Farkas | M | 70 |
European Molecular Biology Organization
| - |
| Matt Roden | M | 53 |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 4 years |
| Robert Kamen | M | 79 |
European Molecular Biology Organization
| 48 years |
| Thomas M. Barnes | M | - |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 4 years |
| Joe Bolen | M | 70 |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 1 years |
| Peter Ratcliffe | M | 69 |
European Molecular Biology Organization
| - |
| Luke O'Neill | M | 60 |
European Molecular Biology Organization
| 19 years |
| Uciane Scarlett | M | - |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 3 years |
| Kurt Faltlhauser | M | 83 |
Ludwig-Maximilians-Universität München
| 37 years |
| John Mattick | M | - |
European Molecular Biology Organization
| - |
| Kevin Johnston | M | - | 2 years | |
| Paul Schulze Lefert | M | - |
European Molecular Biology Organization
| - |
| Dirk Heinz | M | - |
European Molecular Biology Organization
| 15 years |
| Antonio Lanzavecchia | M | 73 |
European Molecular Biology Organization
| - |
| Suzanne Boyd | F | - | 3 years | |
| Karen Vousden | M | 66 |
European Molecular Biology Organization
| - |
| Angela Justice | M | 51 | 5 years | |
| Kellie Neville | F | - |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | 4 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Owen Hughes | M | 49 | 5 years | |
| Christian Itin | M | 59 |
Micromet AG
 Micromet AG Pharmaceuticals: MajorHealth Technology Micromet AG developed, manufactured and marketed novel antibody derived therapeutics for the treatment and control of cancer, inflammatory and autoimmune diseases. It's goal was to commercialize products in these indication areas that have significant unmet medical needs. Founded in 1993, the company was headquartered in Munich, Germany.
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 13 years |
| Jerry Christopher Benjamin | M | 83 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD.
Micromet AG
Micromet AG Pharmaceuticals: MajorHealth Technology Micromet AG developed, manufactured and marketed novel antibody derived therapeutics for the treatment and control of cancer, inflammatory and autoimmune diseases. It's goal was to commercialize products in these indication areas that have significant unmet medical needs. Founded in 1993, the company was headquartered in Munich, Germany. | 5 years |
| Georgia Erbez | F | 57 | 4 years | |
| Shinichiro Fuse | M | - |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts.
iOmx Therapeutics AG
iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | 5 years |
| Scott Myers | M | 57 | 6 years | |
| Christian Rudolf Näther | M | 58 |
Ludwig-Maximilians-Universität München
| 8 years |
| Ulrich Winzenried | M | 69 |
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | - |
| Nisit Khandelwal | M | - |
iOmx Therapeutics AG
iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | - |
| Kapil Dhingra | M | 64 |
Micromet AG
Micromet AG Pharmaceuticals: MajorHealth Technology Micromet AG developed, manufactured and marketed novel antibody derived therapeutics for the treatment and control of cancer, inflammatory and autoimmune diseases. It's goal was to commercialize products in these indication areas that have significant unmet medical needs. Founded in 1993, the company was headquartered in Munich, Germany.
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 3 years |
| Garry Menzel | M | 59 | 7 years | |
| Carsten Reinhardt | M | 57 |
Micromet AG
Micromet AG Pharmaceuticals: MajorHealth Technology Micromet AG developed, manufactured and marketed novel antibody derived therapeutics for the treatment and control of cancer, inflammatory and autoimmune diseases. It's goal was to commercialize products in these indication areas that have significant unmet medical needs. Founded in 1993, the company was headquartered in Munich, Germany.
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 4 years |
| Michael Kemmer | M | 67 |
Ludwig-Maximilians-Universität München
| 5 years |
| Morana Jovan-Embiricos | M | 57 | 6 years | |
| Alexander Dibelius | M | 65 |
Ludwig-Maximilians-Universität München
| 9 years |
| Ron Hunt | M | 59 | 7 years | |
| Matthias Alder | M | 59 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 6 years |
| Gerald McMahon | M | 69 | 5 years | |
| Priti Hegde | M | 52 | 2 years | |
| Sven Oleownik | M | 60 |
Ludwig-Maximilians-Universität München
| 6 years |
| Nicolas Peter | M | 62 |
Ludwig-Maximilians-Universität München
| 5 years |
| Christoph Walbrecht | M | - |
Ludwig-Maximilians-Universität München
| 6 years |
| Victoria Ossadnik | M | 54 |
Ludwig-Maximilians-Universität München
| 9 years |
| Dominique Mohabeer | M | 61 |
Ludwig-Maximilians-Universität München
| 10 years |
| Mark Chin | M | 42 | 7 years | |
| Peter Kossubek | M | 70 |
Ludwig-Maximilians-Universität München
| 8 years |
| Detlef Eberle | M | - |
Ludwig-Maximilians-Universität München
| - |
| Paul Friedrich Lerbinger | M | 68 |
Ludwig-Maximilians-Universität München
| 7 years |
| Dieter Kempf | M | 70 |
Ludwig-Maximilians-Universität München
| 5 years |
| Neil Gibson | M | 67 | 5 years | |
| Michael Feldhahn | M | 70 |
Ludwig-Maximilians-Universität München
| 6 years |
| Ludwig Fuchs | M | 58 |
Ludwig-Maximilians-Universität München
| 5 years |
| Bernhard Scholz | M | 66 |
Ludwig-Maximilians-Universität München
| 12 years |
| Jonathan Drachman | M | 62 | 6 years | |
| Richard Mayer | M | 62 |
Ludwig-Maximilians-Universität München
| 6 years |
| Rudolf Staudigl | M | 69 |
Ludwig-Maximilians-Universität München
| 4 years |
| Cornelius Baur | M | 61 |
Ludwig-Maximilians-Universität München
| 7 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 60 | 60.00% |
| Germany | 45 | 45.00% |
| Switzerland | 2 | 2.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Patrick Baeuerle
- Personal Network